Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products.

Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer READ MORE DATE: August 25, 2020 Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer READ MORE DATE: July 15, 2020 Precision Biologics and the National Cancer Institute deliver 2 Poster Presentations at the AACR virtual meeting June 22-24th, 2020 READ MORE DATE: June 22, 2020 Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research READ MORE DATE: April 30, 2020 Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, that enhance immune killing of tumor READ MORE DATE: February 7, 2020 Phase 1 with Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid tumors READ MORE DATE: January 23, 2020
0
# of people living with cancer in the US
0
annual # of new cases of cancer in the US
0
annual # of deaths from cancer in the US

Discover our innovative Leaders.

Meet our Team